Ubs Group Ag Intellia Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 18,648 shares of NTLA stock, worth $227,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,648

Previous 255,551 92.7%

Holding current value

$227,132

Previous $5.72 Million 93.3%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $451,213 - $626,024	22,881 Added 8.95%	278,432 $5.72 Million
Q2 2024 Aug 13, 2024	SELL	$20.02 - $27.22 $1.52 Million - $2.07 Million	-76,035 Reduced 22.93%	255,551 $5.72 Million
Q1 2024 May 13, 2024	BUY	$23.82 - $32.8 $1.36 Million - $1.87 Million	57,062 Added 20.79%	331,586 $9.12 Million
Q4 2023 Feb 09, 2024	BUY	$23.16 - $32.34 $3.49 Million - $4.87 Million	150,517 Added 121.38%	274,524 $8.37 Million
Q3 2023 Nov 09, 2023	SELL	$31.62 - $45.78 $343,456 - $497,262	-10,862 Reduced 8.05%	124,007 $3.92 Million
Q2 2023 Aug 11, 2023	BUY	$34.58 - $46.03 $1.57 Million - $2.09 Million	45,495 Added 50.9%	134,869 $5.5 Million
Q1 2023 May 12, 2023	SELL	$33.3 - $44.82 $3.07 Million - $4.13 Million	-92,237 Reduced 50.79%	89,374 $3.33 Million
Q4 2022 Feb 08, 2023	BUY	$33.21 - $62.69 $4.41 Million - $8.32 Million	132,643 Added 270.88%	181,611 $6.34 Million
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $110,751 - $147,271	2,054 Added 4.38%	48,968 $2.74 Million
Q2 2022 Aug 10, 2022	SELL	$38.49 - $76.21 $2.01 Million - $3.98 Million	-52,265 Reduced 52.7%	46,914 $2.43 Million
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $930,513 - $1.9 Million	-15,969 Reduced 13.87%	99,179 $7.21 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $5.11 Million - $7.01 Million	50,694 Added 78.65%	115,148 $13.6 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $1.99 Million - $2.66 Million	15,039 Added 30.43%	64,454 $8.65 Million
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $164,132 - $436,509	-2,696 Reduced 5.17%	49,415 $8 Million
Q1 2021 May 12, 2021	SELL	$46.59 - $83.68 $3.44 Million - $6.18 Million	-73,838 Reduced 58.63%	52,111 $4.18 Million
Q4 2020 Feb 11, 2021	BUY	$18.83 - $63.53 $949,276 - $3.2 Million	50,413 Added 66.74%	125,949 $6.85 Million
Q3 2020 Nov 12, 2020	SELL	$17.47 - $24.93 $178,263 - $254,385	-10,204 Reduced 11.9%	75,536 $1.5 Million
Q2 2020 Jul 31, 2020	BUY	$11.14 - $22.87 $45,350 - $93,103	4,071 Added 4.98%	85,740 $1.8 Million
Q1 2020 May 01, 2020	SELL	$9.44 - $15.58 $312,133 - $515,152	-33,065 Reduced 28.82%	81,669 $999,000
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $1.16 Million - $1.96 Million	-110,980 Reduced 49.17%	114,734 $1.68 Million
Q3 2019 Nov 14, 2019	BUY	$13.07 - $18.51 $933,080 - $1.32 Million	71,391 Added 46.26%	225,714 $3.01 Million
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $183,035 - $242,772	13,187 Added 9.34%	154,323 $2.53 Million
Q1 2019 May 14, 2019	SELL	$12.79 - $17.62 $811,717 - $1.12 Million	-63,465 Reduced 31.02%	141,136 $2.41 Million
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $759,735 - $1.81 Million	66,702 Added 48.37%	204,601 $2.79 Million
Q3 2018 Nov 14, 2018	BUY	$25.78 - $32.6 $438,105 - $554,004	16,994 Added 14.06%	137,899 $3.95 Million
Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $1.42 Million - $2.18 Million	-70,711 Reduced 36.9%	120,905 $3.31 Million
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $2.12 Million - $3.81 Million	108,878 Added 131.59%	191,616 $4.04 Million
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $228,052 - $408,107	13,114 Added 18.84%	82,738 $1.59 Million
Q3 2017 Nov 14, 2017	BUY	$15.16 - $25.75 $110,971 - $188,490	7,320 Added 11.75%	69,624 $1.73 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,369 Added 2.25%	62,304 $997,000
Q1 2017 Nov 14, 2017	BUY	N/A	60,935	60,935 $859,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account